Production of [<sup>89</sup>Zr]Oxinate<sub>4</sub> and cell radiolabeling for human use

Massicano, Adriana V F; Bartels, Joachim; Jeffers, Charlotte D.; Crenshaw, Bryant K; Houson, Hailey; Mueller, Christina; Younger, Jarred; Knapp, Paul A.; McConathy, Jonathan; Lapi, Suzanne E.

doi:10.1002/jlcr.3901

Cited by 12 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Efforts have been made to translate 89 Zr-oxine to the clinic. The generation of GMP-compatible 89 Zr-oxine has been reported by different groups using different synthesis methods [60,97], including quality control tests for human use, such as the filter membrane integrity test, endotoxin test, and sterility test [97]. Standardization of GMP-quality 89 Zroxine production will enhance the clinical use of 89 Zr-oxine.…”

Section: Clinical Translation Perspectivementioning

confidence: 99%

Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation

Sato

Choyke

2021

Mol Imaging Biol

View full text Add to dashboard Cite

In the past decades, immunotherapies against cancers made impressive progress. Immunotherapy includes a broad range of interventions that can be separated into two major groups: cell-based immunotherapies, such as adoptive T cell therapies and stem cell therapies, and immunomodulatory molecular therapies such as checkpoint inhibitors and cytokine therapies. Genetic engineering techniques that transduce T cells with a cancer-antigen-specific T cell receptor or chimeric antigen receptor have expanded to other cell types, and further modulation of the cells to enhance cancer targeting properties has been explored. Because cell-based immunotherapies rely on cells migrating to target organs or tissues, there is a growing interest in imaging technologies that non-invasively monitor transferred cells in vivo. Here, we review whole-body imaging methods to assess cell-based immunotherapy using a variety of examples. Following a review of preclinically used cell tracking technologies, we consider the status of their clinical translation.

show abstract

Section: Clinical Translation Perspectivementioning

confidence: 99%

Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation

Sato

Choyke

2021

Mol Imaging Biol

View full text Add to dashboard Cite

show abstract

“…However, there were no significant differences between 89 Zr labeled leukocytes and 111 In labeled leukocytes with respect to elution of activity or cell viability. Another group obtained similar results when using 89 Zr-oxinate4 to label human leukocytes [81]. These results are encouraging, but in vivo investigations of 89 Zr labeled leukocytes to diagnose infection are lacking.…”

Section: Zirconium-89 Labeled Leukocytesmentioning

confidence: 79%

PET Imaging of Infection

Palestro¹

2023

Pericarditis - Diagnosis and Management Challenges

View full text Add to dashboard Cite

Nuclear medicine has played an important part in the diagnosis of infection for 50 years. Gallium-67 citrate was one of the first radionuclides used for diagnosing and localizing infection. The development of techniques for radiolabeling leukocytes and monitoring their migration to foci of infection was a significant advance. More recently, investigators have worked on developing positron-emitting radiopharmaceuticals for diagnosing infection. Positron emission tomography (PET) provides high-resolution three-dimensional images, facilitating precise localization of radiopharmaceutical uptake. Semiquantitative analysis could facilitate the differentiation of infectious from noninfectious conditions and could be used to monitor treatment response. Not surprisingly, the first PET agent investigated was fluorine 18-fluorodeoxyglucose (18F-FDG). Although 18F-FDG has proved to be invaluable for diagnosing infection, it is not specific, and also accumulates in neoplasms, and noninfectious inflammatory conditions. Considerable effort has been devoted to developing PET radiopharmaceuticals that are specific, or at least more specific than 18F-FDG, for infection. Investigators have explored the potential of leukocytes labeled in vitro with various PET radiopharmaceuticals, gallium-68 citrate, gallium-68 labeled peptides, iodine-124 fialuridine, and 18F-fluorodeoxysorbitol. This chapter reviews the role of 18F-FDG for diagnosing infection and monitoring treatment response and other PET agents whose potential for diagnosing infection has been studied.

show abstract

“…The major contributors to loss of 89 Zr activity during the labelling process, which may affect the labelling yield, were the known “stickiness” of 89 Zr and its resultant adherence to surfaces of vials, etc. during labelling (Massicano et al 2020 ), as well as pH adjustment of the [ 89 Zr]Zr-Df-Bz-NCS complex. After chelation, the pH of the [ 89 Zr]Zr-Df-Bz-NCS complex must be neutralised to a pH of 7 for cell labelling.…”

Section: Resultsmentioning

confidence: 99%

89Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations

Kahts,

Guo,

Kommidi

et al. 2023

EJNMMI radiopharm. chem.

View full text Add to dashboard Cite

Background The non-invasive imaging of leukocyte trafficking to assess inflammatory areas and monitor immunotherapy is currently generating great interest. There is a need to develop more robust cell labelling and imaging approaches to track living cells. Positron emission tomography (PET), a highly sensitive molecular imaging technique, allows precise signals to be produced from radiolabelled moieties. Here, we developed a novel leukocyte labelling approach with the PET radioisotope zirconium-89 (89Zr, half-life of 78.4 h). Experiments were carried out using human leukocytes, freshly isolated from whole human blood. Results The 89Zr-leukocyte labelling efficiency ranged from 46 to 87% after 30–60 min. Radioactivity concentrations of labelled cells were up to 0.28 MBq/1 million cells. Systemically administered 89Zr-labelled leukocytes produced high-contrast murine PET images at 1 h–5 days post injection. Murine biodistribution data showed that cells primarily distributed to the lung, liver, and spleen at 1 h post injection, and are then gradually trafficked to liver and spleen over 5 days. Histological analysis demonstrated that exogenously 89Zr-labelled human leukocytes were present in the lung, liver, and spleen at 1 h post injection. However, intravenously injected free [89Zr]Zr4+ ion showed retention only in the bone with no radioactivity in the lung at 5 days post injection, which implied good stability of radiolabelled leukocytes in vivo. Conclusions Our study presents a stable and generic radiolabelling technique to track leukocytes with PET imaging and shows great potential for further applications in inflammatory cell and other types of cell trafficking studies.

show abstract

Production of [⁸⁹Zr]Oxinate₄ and cell radiolabeling for human use

Cited by 12 publications

References 17 publications

Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation

Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation

PET Imaging of Infection

89Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations

Contact Info

Product

Resources

About

Production of [89Zr]Oxinate4 and cell radiolabeling for human use

Cited by 12 publications

References 17 publications

Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation

Whole-Body Imaging to Assess Cell-Based Immunotherapy: Preclinical Studies with an Update on Clinical Translation

PET Imaging of Infection

89Zr-leukocyte labelling for cell trafficking: in vitro and preclinical investigations

Contact Info

Product

Resources

About

Production of [⁸⁹Zr]Oxinate₄ and cell radiolabeling for human use